Nabriva Therapeutics

March 28, 2019

Go or no go? Abbvie, Glaxo and Heron await FDA verdicts

Notable US regulatory decisions due in April feature a major pipeline hope from Abbvie, a non-opioid pain medication from Heron and Glaxo’s two-pill HIV regimen. 

November 30, 2017

Medicines Company shows that there’s money in antibiotics after all

October 18, 2017

Interview – Nabriva comes out fighting

September 19, 2017

A call for help from the antibiotics makers

June 23, 2017

Upcoming events – FDA to discuss Mylotarg again and Nabriva’s pivotal antibiotic data

July 14, 2016

Biotech venture funding falls from 2015 peak

January 18, 2016

Biotechs raise record venture capital haul in 2015

October 05, 2015

Companies edge out of closing IPO window

July 16, 2015

Ferocious venture funding pace eases slightly in Q2